CN111343980B - 右美沙芬经皮递送装置 - Google Patents

右美沙芬经皮递送装置 Download PDF

Info

Publication number
CN111343980B
CN111343980B CN201880072989.3A CN201880072989A CN111343980B CN 111343980 B CN111343980 B CN 111343980B CN 201880072989 A CN201880072989 A CN 201880072989A CN 111343980 B CN111343980 B CN 111343980B
Authority
CN
China
Prior art keywords
dextromethorphan
transdermal delivery
delivery device
day
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880072989.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111343980A (zh
Inventor
S·博萨迪亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New Kai Therapeutics Ltd
Xinkai Treatment Co ltd
Original Assignee
New Kai Therapeutics Ltd
Xinkai Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Kai Therapeutics Ltd, Xinkai Treatment Co ltd filed Critical New Kai Therapeutics Ltd
Publication of CN111343980A publication Critical patent/CN111343980A/zh
Application granted granted Critical
Publication of CN111343980B publication Critical patent/CN111343980B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880072989.3A 2017-10-04 2018-10-03 右美沙芬经皮递送装置 Active CN111343980B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568028P 2017-10-04 2017-10-04
US62/568,028 2017-10-04
US201862680182P 2018-06-04 2018-06-04
US62/680,182 2018-06-04
PCT/US2018/054178 WO2019070864A1 (en) 2017-10-04 2018-10-03 DEVICE FOR TRANSDERMAL DEXTROMETHORPHAN DELIVERY

Publications (2)

Publication Number Publication Date
CN111343980A CN111343980A (zh) 2020-06-26
CN111343980B true CN111343980B (zh) 2024-02-27

Family

ID=65994772

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880072989.3A Active CN111343980B (zh) 2017-10-04 2018-10-03 右美沙芬经皮递送装置

Country Status (13)

Country Link
US (3) US11382869B2 (enExample)
EP (1) EP3691641A4 (enExample)
JP (2) JP2020536953A (enExample)
KR (1) KR20200062254A (enExample)
CN (1) CN111343980B (enExample)
AU (1) AU2018345723B2 (enExample)
BR (1) BR112020006723A2 (enExample)
CA (1) CA3078369A1 (enExample)
IL (1) IL273735B2 (enExample)
MX (1) MX2020003044A (enExample)
TW (1) TWI795446B (enExample)
WO (1) WO2019070864A1 (enExample)
ZA (1) ZA202001834B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795446B (zh) * 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
US20240216358A1 (en) * 2020-03-30 2024-07-04 Shinkei Therapeutics Llc Transdermal delivery of dextromethorphan
CN117100750A (zh) * 2020-07-20 2023-11-24 深圳信立泰药业股份有限公司 一种药物组合物及其应用
JP2024503114A (ja) * 2021-01-18 2024-01-24 アンテシップ バイオベンチャーズ トゥー エルエルシー 神経精神疾患に対する抗うつ剤とデキストロメトルファンとの組み合わせ
CN113720944B (zh) * 2021-09-30 2023-04-28 珠海润都制药股份有限公司 一种氢溴酸右美沙芬硫酸奎尼丁胶囊含量的检测方法
AU2023356341A1 (en) * 2022-10-06 2025-05-15 Shinkei Therapeutics, Inc. Transdermal delivery of dextromethorphan

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04297415A (ja) * 1991-03-27 1992-10-21 Mitsui Petrochem Ind Ltd 薬物投与用粘着剤
US6335030B1 (en) * 1996-04-23 2002-01-01 Pharmacia & Upjohn Ab Transdermally administered dextromethorphan as antitussive agent
WO2015069809A1 (en) * 2013-11-05 2015-05-14 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
WO1995024172A1 (en) * 1994-03-07 1995-09-14 Theratech, Inc. Drug-containing adhesive composite transdermal delivery device
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2004017941A2 (en) * 2002-08-20 2004-03-04 Euro-Celtique, S.A. Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
CA2548596A1 (en) * 2003-12-10 2005-06-23 Acrux Dds Pty Ltd. Method of treatment for undesired effect following transdermal or topical drug delivery
US20060223786A1 (en) 2005-04-01 2006-10-05 Smith David J Transdermal pain control method and device
BRPI0607017B8 (pt) * 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
KR20080097443A (ko) * 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
US20070248657A1 (en) * 2006-04-25 2007-10-25 Smith David J Multi-compartment transdermal pain control device
EA200970369A1 (ru) * 2006-10-09 2009-08-28 Смитклайн Бичам Корпорейшн Композиции для снижения симптомов никотиновой абстиненции и/или отказа от употребления табака
WO2009021058A2 (en) * 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
WO2010062690A1 (en) * 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
JP5680061B2 (ja) * 2009-04-24 2015-03-04 ヘンケル・ユーエス・アイピー・リミテッド・ライアビリティ・カンパニーＨｅｎｋｅｌ ＵＳ ＩＰ ＬＬＣ シリコーンアクリルハイブリッドポリマーを基剤とする接着剤
US20140051718A1 (en) 2012-04-16 2014-02-20 Antecip Bioventures Ii Llc Compositions and Methods Comprising Celecoxib or Related Compounds and Dextromethorphan
TWI795446B (zh) * 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04297415A (ja) * 1991-03-27 1992-10-21 Mitsui Petrochem Ind Ltd 薬物投与用粘着剤
US6335030B1 (en) * 1996-04-23 2002-01-01 Pharmacia & Upjohn Ab Transdermally administered dextromethorphan as antitussive agent
WO2015069809A1 (en) * 2013-11-05 2015-05-14 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dextromethorphan/Quinidine for the Treatment of Pseudobulbar Affect;Edna Patatanian等;《The CONSULTANT PHARMACIST》;第29卷(第04期);第264-269页 *
Simultaneous determination of dextromethorphan and its metabolites in human plasma by capillary electrophoresis;Helle T. Kristensen;《Journal of Pharmaceutical and Biomedical Analysis》;19981201;第18卷;第827-838页 *

Also Published As

Publication number Publication date
IL273735A (en) 2020-05-31
JP7609943B2 (ja) 2025-01-07
TW201922232A (zh) 2019-06-16
AU2018345723B2 (en) 2024-09-19
RU2020115169A3 (enExample) 2022-02-16
MX2020003044A (es) 2020-08-13
CN111343980A (zh) 2020-06-26
ZA202001834B (en) 2024-10-30
BR112020006723A2 (pt) 2020-10-06
CA3078369A1 (en) 2019-04-11
WO2019070864A1 (en) 2019-04-11
IL273735B2 (en) 2024-08-01
RU2020115169A (ru) 2021-11-08
US20220331264A1 (en) 2022-10-20
US11382869B2 (en) 2022-07-12
EP3691641A1 (en) 2020-08-12
IL273735B1 (en) 2024-04-01
KR20200062254A (ko) 2020-06-03
US20240189252A1 (en) 2024-06-13
AU2018345723A8 (en) 2020-04-23
JP2023159366A (ja) 2023-10-31
TWI795446B (zh) 2023-03-11
AU2018345723A1 (en) 2020-04-16
EP3691641A4 (en) 2021-04-07
JP2020536953A (ja) 2020-12-17
US20200323788A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
CN111343980B (zh) 右美沙芬经皮递送装置
JP2023519959A (ja) デキストロメトルファンの経皮送達
JP5795264B2 (ja) 抗認知症薬物の経皮吸収製剤
US11559497B2 (en) Transdermal drug delivery system for ketamine
CN110913844A (zh) 用于氯胺酮的透皮药物递送系统
EP3498272B1 (en) Oxybutynin-containing transdermal absorption preparation
EP4076382B1 (en) Transdermal therapeutic system containing agomelatine
RU2795729C2 (ru) Устройство для трансдермальной доставки декстрометорфана
HK40028806B (zh) 右美沙芬经皮递送装置
HK40028806A (en) Dextromethorphan transdermal delivery device
JP2025532367A (ja) デキストロメトルファンの経皮送達
HK40082932A (en) Transdermal therapeutic system containing agomelatine
KR101964295B1 (ko) 피부 자극이 감소된 메만틴 경피전달 시스템

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40028806

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: New Jersey USA

Applicant after: New Kai Therapeutics Ltd.

Address before: New Jersey USA

Applicant before: Xinkai treatment Co.,Ltd.

Country or region before: U.S.A.

GR01 Patent grant
GR01 Patent grant